Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI tool automates liver tumor detection and monitoring

2.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

3.

Year in Review: Multiple Myeloma

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Breast Cancer Incidence Rises in Asian American Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot